Skip to main content
Nicholas Marston, MD, Cardiology, Boston, MA, Brigham and Women's Hospital

NicholasMarstonMDMPH

Cardiology Boston, MA

Preventive Cardiology, Cardiovascular Disease Genetics

Cardiologist, Brigham and Women's Hospital | Investigator, TIMI Study Group

Dr. Marston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Marston's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2016 - 2020
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterChief Residency, Internal Medicine, 2015 - 2016
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterResidency, Internal Medicine, 2012 - 2015
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 2012

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - Present
  • MA State Medical License
    MA State Medical License 2016 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Journal Articles

  • Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines  
    Nicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology

Authored Content

  • Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020

Press Mentions

  • ApoB Gains Ground as Best Lipid Predictor of MI Risk
    ApoB Gains Ground as Best Lipid Predictor of MI RiskNovember 22nd, 2021
  • No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER
    No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIERSeptember 2nd, 2021
  • AHA 2020: PCSK9 Inhibition as Primary Prevention for VTE: Is It LDL or Lp(A)?
    AHA 2020: PCSK9 Inhibition as Primary Prevention for VTE: Is It LDL or Lp(A)?December 23rd, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations